Printed from Voxsanity (voxsanity.com.au) — NCT07562659 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Colorectal Cancer
Phase 2 Colorectal Cancer Trial, Recruiting
NCT07562659
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 or older, of any sex
- People whose general health and ability to carry out daily activities falls within an acceptable range on a standard medical scale (ECOG score of 0–2), with a life expectancy of more than 3 months
- People who have been diagnosed through laboratory testing with high-risk stage II colorectal cancer after surgery
- People who have a specific cancer marker in their blood (called ctDNA) that tested positive about one month after their surgery
- People with a life expectancy of more than 12 months
- People who are able to understand and sign a consent form agreeing to take part in the study (this can be done through a legal guardian or representative if needed)
Who may not be able to join:
- People who received cancer treatment (such as chemotherapy or radiation) before their surgery
- People who received a blood transfusion during surgery or in the two weeks before surgery
- People who are pregnant or breastfeeding, or people who are capable of having children and are not using adequate contraception
- People who have been diagnosed with another cancer in the past 5 years (exceptions may apply for certain early-stage cervical or skin cancers — confirm with trial site)
- People who have uncontrolled brain tumours or cancer that has spread to the brain or nervous system, or who have significant pressure in the brain or serious neurological or psychiatric symptoms
- People with serious or uncontrolled health conditions, including: unstable heart conditions such as heart attack, heart failure, unstable chest pain, or irregular heartbeat within the past 6 months; diagnosed neurological or psychiatric conditions such as dementia or seizure disorders; severe or uncontrolled infections; active bleeding disorders; significant loss of function in major organs; or any other condition the trial doctors consider would make participation unsafe
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Recruiting
Phase
Phase 2
Sponsor
Registry
ClinicalTrials.gov
Start date
1 November 2024
Est. completion
31 December 2027
Where this trial is recruiting
🇨🇳 China
Primary endpoints
Patient's 2-year Progression-Free Survival
Can't join this trial?
Data last synced from ClinicalTrials.gov: 2 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.